Wall Street analysts forecast that ConforMIS Inc (NASDAQ:CFMS) will report earnings of ($0.16) per share for the current quarter, according to Zacks. Three analysts have issued estimates for ConforMIS’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.19). ConforMIS posted earnings of ($0.27) per share in the same quarter last year, which would suggest a positive year over year growth rate of 40.7%. The firm is scheduled to issue its next earnings report on Wednesday, February 6th.
According to Zacks, analysts expect that ConforMIS will report full year earnings of ($0.82) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.79). For the next financial year, analysts expect that the firm will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.54) to ($0.44). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for ConforMIS.
ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, October 31st. The medical instruments supplier reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.08. The business had revenue of $28.98 million for the quarter, compared to analyst estimates of $19.21 million. ConforMIS had a negative return on equity of 90.97% and a negative net margin of 51.25%.
CFMS has been the topic of a number of research analyst reports. SunTrust Banks restated a “buy” rating on shares of ConforMIS in a research report on Monday, July 16th. Zacks Investment Research upgraded ConforMIS from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, July 18th. BTIG Research restated a “buy” rating and set a $3.00 price target on shares of ConforMIS in a research report on Thursday, August 2nd. Oppenheimer set a $4.00 price target on ConforMIS and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Finally, Canaccord Genuity decreased their price target on ConforMIS from $3.00 to $2.50 and set a “buy” rating on the stock in a research report on Thursday, November 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $2.45.
A number of large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in ConforMIS by 79.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 91,356 shares of the medical instruments supplier’s stock worth $132,000 after buying an additional 40,563 shares in the last quarter. BlackRock Inc. lifted its holdings in ConforMIS by 2.6% during the 1st quarter. BlackRock Inc. now owns 2,398,722 shares of the medical instruments supplier’s stock worth $3,478,000 after buying an additional 61,539 shares in the last quarter. Spark Investment Management LLC lifted its holdings in ConforMIS by 60.5% during the 2nd quarter. Spark Investment Management LLC now owns 193,989 shares of the medical instruments supplier’s stock worth $242,000 after buying an additional 73,089 shares in the last quarter. Northern Trust Corp lifted its holdings in ConforMIS by 20.2% during the 1st quarter. Northern Trust Corp now owns 538,985 shares of the medical instruments supplier’s stock worth $782,000 after buying an additional 90,447 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new position in ConforMIS during the 2nd quarter worth $131,000. 40.15% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ CFMS opened at $0.63 on Friday. The company has a market cap of $39.24 million, a P/E ratio of -0.51 and a beta of 1.23. ConforMIS has a one year low of $0.60 and a one year high of $3.83. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.15 and a current ratio of 5.71.
ConforMIS, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Read More: Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.